INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or pr...

Full description

Saved in:
Bibliographic Details
Main Authors ANZHELIKA KABRO, STEPHANE CIBLAT, KENNETH MATTHEW WHITMORE, ROBERT ZAHLER, DARBY SCHMIDT, KATE-LYN LUND, STEPHANIE ROY, KEVIN SPROTT, JASON J MARINEAU, HENRI PIRAS, GORAN MALOJCIC, DANA K WINTER, WILLIAM SINKO, CLAUDIO CHUAQUI
Format Patent
LanguageEnglish
Published 26.06.2024
Online AccessGet full text

Cover

More Information
Summary:The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
Bibliography:Application Number: ZA20230001672